ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
- First Posted Date
- 2003-02-07
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00054691
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
- Conditions
- Interventions
- First Posted Date
- 2003-02-07
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 94
- Registration Number
- NCT00050531
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Docetaxel in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT00008411
- Locations
- 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸University of Texas M.D. Anderson CCOP Research Base, Houston, Texas, United States
Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00052221
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00006471
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 265
- Registration Number
- NCT00024167
- Locations
- 🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸University of Mississippi Cancer Clinic, Jackson, Mississippi, United States
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 306
- Registration Number
- NCT00002855
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT00046865
- Locations
- 🇺🇸
University of Texas M.D. Anderson CCOP Research Base, Houston, Texas, United States
🇺🇸H. Lee Moffitt Cancer Center CCOP Research Base, Tampa, Florida, United States
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00023881
- Locations
- 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT00002882
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States